Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Biotech Startup Investors in April 2025

Last updated: Apr 2025 A list of 50 angel investors and VC (Venture Capital) funds that invest in Biotech startups. We rank investors based on the number of investments they made in Biotech companies. This investor list updates every month.

Top 50 Biotech Startup Investors in April 2025

Investor	Biotech investments
SOSV	261
ARCH Venture Partners	131
OrbiMed	105
Sofinnova Partners	98
Alexandria Venture Investments	97
Novo Holdings	88
Versant Ventures	84
F-Prime Capital	79
New Enterprise Associates	76
Atlas Venture	73
RA Capital Management	71
Khosla Ventures	69
Qiming Venture Partners	66
Polaris Partners	66
5AM Ventures	65
Bpifrance	64
MPM Capital	63
Novartis Venture Fund	63
Innova Memphis	63
Third Rock Ventures	60
M Ventures	60
High-Tech Gruenderfonds	58
UK Innovation & Science Seed Fund	58
HSG	56
BioAdvance	52
Lilly Asia Ventures	51
Google Ventures	51
Canaan Partners	51
Pfizer Venture Investments	50
Boehringer Ingelheim Venture Fund	50
Fifty Years	47
Andreessen Horowitz	47
Lux Capital	47
DCVC	47
SR One	47
EQT Life Sciences	46
Takeda Ventures	45
Parkwalk Advisors	45
Seventure Partners	45
Sofinnova Investments	45
The Column Group	44
Forbion Capital Partners	44
KdT Ventures	43
Casdin Capital	41
Eli Lilly	41
Hatteras Venture Partners	41
Scottish Enterprise	40
Connecticut Innovations	40
Dolby Family Ventures	39
Oxford Science Enterprises	39

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, China, United Kingdom

Portfolio highlights

Rhygaze — RhyGaze is at the forefront of developing a novel first-in-class gene therapy aimed at improving vision in patients suffering from retinal diseases.
Kardigan — Kardigan is building the heart health company of the future focused on developing medicines to make cardiovascular disease curable, preventable, and no longer the leading cause of death.
Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.

Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, China, Israel

Portfolio highlights

vVardis — vVardis is a personal oral care brand by Dres Abivardi.vVardis is both the professional dental CURODONT™ line and the oral care vVardis products – both with the proprietary CUROLOX® & WX Technology – will form one oral care powerhouse.
Stairway Medical — Stairway Medical is a developer of implantable brain-computer interface technology.
Helicore Biopharma — Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
Latent Labs — Latent Labs is making biology programmable to transform health and sustainability for the benefit of all.We are a frontier AI lab building foundational models that capture the fundamentals of biology. We empower partners with breakthrough generative AI to gain unprecedented control over molecular biology, creating new antibodies, optimizingexisting enzymes, and advancing genetic engineering.Contact us to work with us today.
Berry Street — Nutrition therapy by registered dietitians covered by insurance.

Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Canada, France

Portfolio highlights

Meiogenix — Meiogenix is a biotech company developing breeding technologies to unlock the unexplored genetic diversity of organisms. Meiogenix expands the natural biodiversity and helps developing new products to address global food and industrial challenges.
nChroma Bio — nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.
Nuvig Therapeutics — Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inﬂammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmunediseases.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

Supira Medical — Next Generation Solution for Temporary Mechanical Circulatory Support Developing a low-profile, high-flow percutaneous ventricular assist device (pVAD) for high risk coronary intervention and cardiogenic shock. Clinical Need Percutaneous ventricular assist devices (pVADs) are placed to provide temporary mechanical support, assisting the native pumping action of
Callio Therapeutics — Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.
Newleos Therapeutics — Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Switzerland, Canada

Portfolio highlights

Antag Therapeutics — Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner.
Helicore Biopharma — Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders.
Light Horse Therapeutics — Light Horse Therapeutics is the gene editing applied to small-molecule drug discovery, pioneering approaches to target the root causes of disabling and life-threatening diseases. Its advanced platform identifies cryptic chemically accessible functional domains within targets that are critical in disease biology. Our initial focus addresseshigh-value, historically challenging oncology targets with the opportunity to apply the technology to other therapeutic areas in the future.

F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, United Kingdom, China

Portfolio highlights

Ethena — Enabling the Internet Bond
Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.
Bluebird Kids Health — Bluebird Kids Health is launching a proprietary technology platform to proactively manage and coordinate treatment, with AI enhancing and simplifying the experience for its clinical team.

Foundational partners to ambitious founders at every stage of company-building.

Investment focus

Software, Health Care, Biotechnology
Series B, Series A, Series C
United States, India, Canada

Portfolio highlights

Ceramic.ai — Ceramic.ai builds enterprise-grade infrastructure to optimize how companies train and deploy their AI models
Vori Health — Meet Vori Health, the new virtual and in-person musculoskeletal healthcare company that will help you get that spring back into your step.
Ceramic — Next generation AI training systems for better models with less compute, less time, and lower costs.

Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Judo Bio — Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new treatments for systemic and renal diseases.
Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series C, Post-IPO Equity
United States, United Kingdom, Canada

Portfolio highlights

Curevo — focused on a new generation of adjuvanted subunit vaccines Learn More Our Focus We're dedicated to developing non-mRNA vaccines for unmet medical needs Curevo Vaccine is a clinical-stage biotech company dedicated to developing next-generation non-mRNA vaccines. We focus on one need at a time, allowing us to bring effective and better-tolerated vaccines to market quickly
Surrozen — Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including diseases of the intestine, liver, retina,cornea, lung, kidney, cochlea, skin, pancreas and central nervous system.
Vivace Therapeutics — Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway. At Vivace Therapeutics, they pursue their work with passion, driven by a conviction to help people fight cancer and live life to the fullest. Based in the San Francisco Bay Area, Vivace Therapeutics is anoncology-focused portfolio-based drug discovery and development company adopting a capital-efficient and modality-indifferent approach to bring novel therapies to patients in need. Their experienced management team and world-class scientists work to advance promising drugs and therapeutic technologies that they believe can help conquer cancer.

Khosla Ventures invests in companies that are bold, early, and impactful. The firm was started in 2004 by Vinod Khosla, co-founder of Sun Microsystems, to provide venture assistance to entrepreneurs.Khosla Ventures invests in a range of areas including AI, climate, sustainability, enterprise, consumer, fintech, digital health, medtech anddiagnostics, therapeutics, and frontier technology.

Investment focus

Software, Health Care, Artificial Intelligence
Series A, Series B, Seed
United States, India, United Kingdom

Portfolio highlights

Onyx — The open-source AI enterprise search platform that helps teams find information across all company data.
Tempero Bio — Tempero Bio develops treatments for Substance Use Disorders as a clinical-stage biopharmaceutical company.
Resource Chemical — Resource Chemical develops CO2 into high-performance plastics that do not pollute the environment. The company's headquarters are in Berkeley, California.

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.

Investment focus

Health Care, Biotechnology, Medical
Series B, Series A, Series C
China, United States, Hong Kong

Portfolio highlights

Stairway Medical — Stairway Medical is a developer of implantable brain-computer interface technology.
Xinzeyuan Medical — Xinzeyuan Medical is a manufacturer of key precision components and medical endoscope consumables.
Iongen Therepeutics — Iongen Therepeutics is an innovative drug research and development company focusing on pain treatment.

Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.

Investment focus

Health Care, Biotechnology, Medical
Series B, Series A, Series C
United States, Ireland, Singapore

Portfolio highlights

FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
Leyden Labs — Leyden Labs helps people live freely by developing products that protect from known and new respiratory viruses.
Auron Therapeutics — A differentiated approach to cure cancer.

5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

RareCyte — Rarecyte provides precision medicine solutions focused on multiplexed analysis of cells and tissue with applications in both research and clinical diagnostics.
TMRW Life Sciences — TMRW helps patients and clinics safely store their eggs and embryos
Latigo Biotherapeutics — Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability.

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.

Investment focus

Software, Information Technology, Health Care
Seed, Funding Round, Series A
France, United States, Switzerland

Portfolio highlights

Terratis — Terratis is a French company that uses the Sterile Insect Technique (SIT) to reduce the populations of tiger mosquitoes and agricultural pests. Their mission is to diminish harmful insect populations effectively on a large scale using a scientific, innovative, ecological, and efficient approach.
Ochy — Ochy is an app that uses AI to analyse running form and gait to identify weak points and provide recommendations on what to do to improve.
MB Therapeutics — MB Therapeutics is a pharmaceutical firm that provides patient-centric solutions for developing and producing tailored medicines.

Powering Breakthroughs in Life Sciences

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series B, Series A, Series C
United States, United Kingdom, Canada

Portfolio highlights

Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
Umoja Biopharma — Pioneering immunotherapy by reprogramming T cells in vivo to target cancer cells.
Frontier Medicines — Frontier Medicines is boldly advancing science to defeat disease by pioneering innovations in precision-based medicines to target undruggable therapies

Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Rhygaze — RhyGaze is at the forefront of developing a novel first-in-class gene therapy aimed at improving vision in patients suffering from retinal diseases.
Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.
Alesta Therapeutics — Alesta Therapeutics pioneers innovative small molecule therapies for rare diseases, including hypophosphatasia and Charcot-Marie-Tooth

Founded in 2007 by the Memphis Bioworks Foundation, Innova is a pre-seed, seed and early-stage investor focused on starting and funding high-growth companies in the Biosciences, Technology and AgBio fields across the state of Tennessee. Innova links capital with great ideas to create groundbreaking products and services.At Innova we invest instart-up companies, help them grow, and then assist them in linking with established corporations for licensing, buy-outs or further investments. We provide the synergy of experienced management, market expertise and venture capital to accelerate the development of new products and services into viable business units that can stand on their own and then take their place with a mature market leader, if desired.Whether an innovation is still on the drawing board or stalled in the market place the Innova staff has the expertise, skills, and experience to envision and create a functioning business unit that is prepared to thrive in the market place. Technical know-how, market-proven staffing, and "just-right" funding assure the greatest chance possible for success.

Investment focus

Health Care, Medical, Medical Device
Seed, Pre-Seed, Convertible Note
United States, Argentina, United Kingdom

Portfolio highlights

Rantizo — Fly more acres, deliver better service. The equipment, tools, and expertise you need to be the grower's first call for drone spray services.
HerdDogg — HerdDogg is passionate about livestock. Its innovative data platform sits at the intersection of agtech, the internet of things, and global food security. Our patented DoggTags and DoggBone, together with our Animal Traceability Platform, help producers make more money from every animal they raise. The HerdDogg system enables animal tracking,welfare monitoring and traceability in an easy-to-use application. For more information, visit herddogg.com.
iYOTAH Solutions — Take your dairy operation to the next level. Our state of the art platform helps you save time, increase efficiencies and profits and unlock new opportunities.

Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States

Portfolio highlights

Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
Candid Therapeutics — Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.
Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

IonKraft — IonKraft can provide better performance at a lower cost while maintaining recyclability, they also promote material reduction and reuse and are commercializing the technology with funding from the German Federal Ministry for Economic Affairs and Energy (BMWi).
NovoLINC — NovoLINC is a pioneering startup that provides thermal interface solutions. It develops a distinctive system of nanostructured materials and a proprietary manufacturing process with the objective of transforming thermal management.
TRIMTECH Therapeutics — TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD).

The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Investment focus

Software, Biotechnology, Information Technology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

AICA SA — AICA believes programming robots should be at everyone's reach. We combine Artificial Intelligence & an intuitive interface, to help you relocate your production.
ctrl+s — High resolution insights into the deep supply chain are the building blocks for every substantive sustainability strategy and effective decarbonization.
Akribion Genomics — Specific, versatile, effective RNA-guided cell depletion

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
Antiverse — Designing biologics for 100 challenging targets
iFast Diagnostics — iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.

We help founders build enduring companies.

Investment focus

Health Care, Biotechnology, Software
Series A, Series B, Series C
China, United States, Hong Kong

Portfolio highlights

Manus AI — Manus is a general AI agent that bridges thoughts and actions by excelling in various tasks such as research, data analysis, education, and productivity, offering personalized solutions across different domains to help users achieve their goals efficiently.
RedotPay — RedotPay is a leading crypto fintech bridging Web3 and traditional finance through innovative, cost-efficient blockchain solutions. Our intuitive crypto payment products enable millions of users globally to easily spend and send digital assets. We foster financial inclusion for the unbanked and serve crypto enthusiasts, advancing global adoption offast, accessible crypto payments.
Danking Pharmaceuticals — Danking Medicine is an innovation-driven drug developer.

BioAdvance actively invests venture capital in therapies, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region.

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United States, Canada

Portfolio highlights

KayoThera — KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is todevelop the first-in-class immuno- and targeted therapies to drive cures in advanced cancersKayoThera was founded in 2019 and is headquartered in Princeton, New Jersey.
Tolerance Bio — Tolerance Bio will increase health span by preserving and restoring the function of the thymus, the master regulator of immune tolerance. Immune-mediated diseases represent a significant unmet medical challenge: cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergi
Vittoria Biotherapeutics — Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings.

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
China, United States, Hong Kong

Portfolio highlights

Fine Vision — Fine Vision is a company with R&D facilities in Nanjing and Wuhan that focuses on femtosecond laser application research in the fields of ocular surgery and biomaterial processing. The entire femtosecond laser corneal refractive surgery equipment, its first commercially available item, was developed by the university's WuhanOptoelectronics National Research Center under the Huazhong Technology Technology transition.
Verdiva Bio — Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.
Stairway Medical — Stairway Medical is a developer of implantable brain-computer interface technology.

GV supports innovative founders moving the world forward.

Investment focus

Software, Health Care, Biotechnology
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

comstruct — comstruct is working on a platform that will allow construction companies to digitize and automate material purchasing. All delivery bills, invoices, and purchase orders, as well as processes such as invoice verification, can be exchanged digitally with suppliers. All data pertaining to the purchasing process is made available for documentation,evaluation, and process optimization.
Mimic Networks — Mimic's new enterprise ransomware defense technology provides a last line of defense against ransomware attacks and protects your critical data against theft and encryption.
Perceive Pharma — Perceive Pharma operates as a pharmaceutical company. Perceive Pharma develops innovative small molecule neuroprotective treatments.

Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.

Investment focus

Software, Biotechnology, Health Care
Series A, Series B, Series C
United States, United Kingdom, Israel

Portfolio highlights

WiseLayer — WiseLayer's AI empowers finance teams to improve profitability & efficiency in minutes per week
Enterpret — All customer feedback categorized automatically, combined with advanced analytics capabilities that ensure no customer pain goes unnoticed.
Wise Layer — WiseLayer makes AI-powered digital workers for finance and accounting teams.It's AI digital workforce includes: - Angela, the AI agent for Accruals & Rev Rec (hire her at www.accruals.ai) - Dennis, the AI agent for Discrepancies & Financial Anomalies (hire him at www.discrepancies.ai) - … with the 4 newest AI agents eachspecializingin the following tasks: (1) bank reconciliations, (2) fixed asset depreciation & amortization, (3) lease accounting, and (4) prepaid expenses.

Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, United Kingdom, Switzerland

Portfolio highlights

TRex Bio — TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis.
Normunity — We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
TRIMTECH Therapeutics — TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD).

Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
Asgard Therapeutics — Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biologicalproperties of professional antigen-presenting cells.

WE BACK HEROES using technology to solve the world's biggest problems

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, Germany, Canada

Portfolio highlights

Gridware — Using remote telemetry and edge AI, Gridware wildfire prevention technology powers a grid that is smarter and more reliable than ever before.
Aalo Atomics — Creating abundant and dependable clean energy to power humanity for generations.
Waypoint Bio — Waypoint's proprietary spatial multi-omics platform enables us to solve critical issues around understanding how cell therapies navigate the three-dimensional tumor microenvironment and allow the measurement of cell-to-cell interactions.

Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.

Investment focus

Software, Information Technology, Internet
Series A, Seed, Series B
United States, United Kingdom, Brazil

Portfolio highlights

Flock Safety — From creating safer neighborhoods to protecting employees and property, we help you deter and solve crime with tools customized and scaled to your needs.
Rune Technologies — Rune Technologies' objective is to consistently deliver innovative logistics technology to support the free world's enduring values, enable quick triumphs, and maintain peace through strength.
Mercury — Powerful banking. Simplified finances. Apply in 10 minutes for business banking that transforms how you operate.

Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.

Investment focus

Software, Health Care, Biotechnology
Series A, Seed, Series B
United States, United Kingdom, Canada

Portfolio highlights

Lanai — The AI Empowerment Platform - Help your team achieve the extraordinary in the age of AI.
Ramp — Join thousands of forward-thinking businesses using Ramp to control spend, save time, and automate busywork.
Frontera Health — Save 5-6 hours on every ABA diagnosis and assessment report. Frontera ABA clinical report automation software helps you spend more time with patients. Let our BCBA-trained AI do the heavy lifting.

We are deep tech venture capital.

Investment focus

Software, Artificial Intelligence, Health Care
Seed, Series A, Series B
United States, Canada, United Kingdom

Portfolio highlights

Lumafield — Lumafield's easy-to-use CT scanner and cloud-based software give engineers the ability to see their work clearly, inside and out.
Fervo Energy — Fervo Energy delivers 24/7 carbon-free energy through development of next-generation geothermal projects.
Alta Resource Technologies — Alta Resource Technologies is on a mission to reinvent mining by harnessing advanced biochemistry to cost-effectively source the critical raw materials needed to power next-generation technology and bolster economic security. Our groundbreaking technology platform leverages customizable proteins to separate high-purity rare earth elements and otheressential minerals with unprecedented selectivity while dramatically reducing the environmental impact of mining.

SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Windward Bio — Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
Antag Therapeutics — Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner.
Kala Pharmaceuticals — Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high,sustained local drug concentrations with reduced systemic exposure and are delivered in a patient-friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept while establishing R&D collaborations with select partners to improve products in their pipelines.

Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, The Netherlands, Switzerland

Portfolio highlights

XyloCor Therapeutics — XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patientswith refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively.
Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.
Tenpoint Therapeutics — Tenpoint Therapeutics Ltd. is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye.

Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Funding Round
United States, United Kingdom, Israel

Portfolio highlights

Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Larkspur Biosciences — Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system.
EvolveImmune Therapeutics — EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases.

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Investment focus

Biotechnology, Health Care, Software
Seed, Series A, Series B
United Kingdom, United States, Philippines

Portfolio highlights

Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
illumion — Illumion develops high-throughput optical tools to accelerate battery material development
Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.

Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion undermanagement as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy

Investment focus

Biotechnology, Health Care, Software
Series A, Funding Round, Series B
France, United States, Germany

Portfolio highlights

Ekstere — Ekstere facilitates selling and purchasing verified-quality used bicycles at a reasonable price.
Anybuddy — Anybuddy is a sport booking marketplace, leader in racket sport in France
Seaweed Concept — Seaweed Concept is a marine biotechnology company, that focuses on the innovative utilization of seaweed to provide high-quality ingredients to various industrial sectors

Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series B, Series A, Series C
United States, France, Switzerland

Portfolio highlights

Axonis Therapeutics — AXONIS Therapeutics, Inc. is advancing breakthrough discoveries to develop first-in-class therapies for neurological disorders.
Avenzo Therapeutics — Developing the next generation of oncology therapies for patients.
Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.

The Column Group (TCG) is a venture ecosystem dedicated to fueling scientific innovation in the life sciences industry.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States

Portfolio highlights

Rapt Therapeutics — RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company is developing highly selectivesmall molecules designed to modulate the critical immune responses underlying these diseases. In its first four years since inception, RAPT has discovered and advanced two unique drug candidates, each targeting C-C motif chemokine receptor 4. The company’s lead oncology drug candidate, FLX475, reached the clinic in just two and a half years with its lead inflammation drug candidate, RPT193, also in the clinic. The company is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, that are in the discovery stage of development.
Nura Bio — Nura Bio revolutionizes the treatment of neurological diseases with novel, life-changing neuroprotective medicines. Nura Bio was conceived in 2018 by The Column Group and its scientific founders.
Circle Pharma — Circle Pharma is an early-stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell-permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diversemacrocycle scaffolds selected for inherent permeability. The company was founded by Matt Jacobson and Scott Lokey in 2012 and is headed by David J. Earp.

Impacting the future of medicine.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, The Netherlands

Portfolio highlights

Numab — Numab Therapeutics AG
Verdiva Bio — Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.
Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.

KdT Ventures is the standard for early-stage frontier science investing.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, Israel, Germany

Portfolio highlights

Shiprocket — Shiprocket is India's most-used eCommerce logistics and shipping software solution for the best courier services. Avail features like COD (Cash on Delivery), prepaid delivery, automated shipping, etc.
March Biosciences — Transforming Patient Care by Unlocking New Target Spaces March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity
Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases

Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, France, China

Portfolio highlights

Leyden Labs — Leyden Labs helps people live freely by developing products that protect from known and new respiratory viruses.
nChroma Bio — nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.
Auron Therapeutics — A differentiated approach to cure cancer.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conductsresearch to find products to treat diseases in animals and to increase the efficiency of animal food production.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Funding Round
United States, United Kingdom, Canada

Portfolio highlights

Maxion Therapeutics — Maxion Therapeutics helps in learning transformative therapies. It uses this technology to deliver long-acting, safe, and effective medications against previously inaccessible targets.
Ampersand Biomedicines — Ampersand is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability.
Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.

Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Funding Round
United States, Canada

Portfolio highlights

Endogenex — DyaMX is an early stage medical device company focused on the treatment of Type 2 Diabetes
Synaptrix — Synaptrix is a medical device start-up company dedicated to developing and commercializing drug-free pain management solutions for postoperative joint surgery patients. The proprietary NOVABLOC system is a procedure-based solution that delivers a novel type of electrical stimulation. Human feasibili
AtaCor Medical — AtaCor Medical Inc., is a San Clemente-based medical device maker. It designs innovative solutions to deliver temporary, interim, and permanent cardiac pacing when, and where it matters most.

Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.

Investment focus

Biotechnology, Software, Health Care
Grant, Funding Round, Seed
United Kingdom, United States, Japan

Portfolio highlights

Sisaltech — Sisaltech a natural fiber from the Agave plant, is durable, biodegradable, and has low environmental impact in production. Sisaltech makes the use of these in building insulation a very eco-friendly choice.
Kaly Group — KALY is like an intriguing group based on the description, it appears to be a collective of individuals with diverse interests and passions—innovators, sailors, and nature enthusiasts—coming together with a shared mission of exploration and discovery.
Scotmas Group — Scotmas are specialists in Chlorine Dioxide (ClO2) generators & dosing systems for drinking water treatment, Legionella control and SWRO.

At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Funding Round
United States, Israel, Canada

Portfolio highlights

Normunity — We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
VeraDermics — VeraDermics Inc. is a dermatology pharmaceutical start-up, makers of WartPatch
PHȲND — PHȲND is a subscription-free cloud gaming platform that offers a way to discover, play, and socialize across a wide variety of games.

Investing in early-stage companies solving the biggest science and engineering challenges since 2014.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Seed, Series B
United States, Austria, Switzerland

Portfolio highlights

Vandria — At the vanguard of Mitochondrial research
Calicat — H2UTechnologies -Co-founded by Motus Ventures and H2U Chief Scientific Advisor, Dr Nathan Lewis-George L. Argyros Professor of Chemistry at the California Institute of Technology and founding Director and Scientific Director of JCAP (Joint Center for Artificial Photosynthesis)/Cal Tech...clean energy
NeuroBionics — NeuroBionics aims to advance neurotech and human health through bioelectronic medicine, by developing devices that seamlessly integrate with the human body.

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Series B
United Kingdom, United States, Finland

Portfolio highlights

FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Neu Health — Neu Health enables clinicians, care givers and patients to tackle this growing challenge with cutting-edge digital technologies designed to make the latest care accessible for all, improving outcomes today and accelerating future breakthroughs.
Salience Labs — Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany.

Investors by industry